Newly published data on the postprandial kinetics of apoB48 and B100 in chylomicrons, VLDL1, VLDL2, IDL and LDL, in people heterozygous for a loss-of-function (LOF) mutation in the APOC3 gene, indicate the potential benefits of apoCIII lowering for cardiovascular disease (CVD) prevention.
Professor John Chapman (Pitié-Salpetrière University Hospital, INSERM, Paris France) discusses the crucial role of cholesterol crystals in atherothrombosis and the evidence suggesting that ethyl eicosapentaenoic acid may modify crystal formation and deposition, with implications for therapeutic intervention in atherosclerotic cardiovascular disease (ASCVD).
Very elevated (>75th percentile) non-fasting REM-C or non-fasting TG deserve further evaluation as a potentially valuable modifier of atherosclerotic cardiovascular disease risk. Replication of current findings could potentially improve the care of patients at risk of ischaemic events.
New guidance about the use of icosapent ethyl (Vazkepa) for reducing cardiovascular (CV) risk, issued by the National Institute for Health and Care Excellence (NICE), is expected to benefit around 425,000 people in England treated on the country’s free National Health Service (NHS). NICE has recommended icosapent ethyl as an option for reducing the risk of CV events (eg. myocardial infarction and stroke) in adults.
The recently published European Atherosclerosis Society (EAS) consensus statement on triglyceride-rich lipoproteins (TRLs) and their remnants provides a critical appraisal of current understanding of the structure, function, and metabolism of TRLs, and their pathophysiological role in atherosclerotic cardiovascular disease (ASCVD).1
Professor Gary Lewis, Director of the Banting and Best Diabetes Centre at the University of Toronto, Canada, and co-author of this important EAS publication, discusses the evidence and its implications for clinicians and patients.
The ink was barely dry on the 2018 American Heart Association (AHA) and American College of Cardiology (ACC) cholesterol management guidelines1 when new evidence from the REDUCE-IT trial supported a possible role for icosapent ethyl in reducing cardiovascular risk in patients with persistent hypertriglyceridaemia despite the use of statins.2 As a result, the ACC has produced further guidance on the management of patients with persistent hypertriglyceridemia,3 as Dr Michael Miller, Professor of Cardiovascular Medicine at the University of Maryland, Baltimore, USA, and co-author of the publication explains.